首页> 美国卫生研究院文献>Romanian Journal of Ophthalmology >Generics versus brand-named drugs for glaucoma: the debate continues
【2h】

Generics versus brand-named drugs for glaucoma: the debate continues

机译:泛型与青光眼的品牌药物:辩论继续

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy.
机译:给定类药物有三种选择,包括品牌药物,通用和品牌仿制药。品牌名称药物与普通和品牌仿制药相比,他们是经过多年的研究经过多年的专利开发的创新者分子,而品牌通用药物由不同的公司生产一旦专利创新公司到期。鉴于青光眼是一种慢性,主要是无症状的疾病,药物的选择非常重要:药物的持续时间通常是终身,药物的成本,副作用和疗效影响遵守和依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号